Inventor
BHANDARI ASHOK
US30 patents
⚠️ This page may combine multiple inventors who share the name “BHANDARI ASHOK”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
PROTAGONIST THERAPEUTICS INC
24 patentsUS9518091B2Dec 13, 2016
A4B7 peptide monomer and dimer antagonists
PROTAGONIST THERAPEUTICS INC34 citations98
US9624268B2Apr 18, 2017
Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
PROTAGONIST THERAPEUTICS INC40 citations97
US10941183B2Mar 9, 2021
Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
PROTAGONIST THERAPEUTICS INC13 citations94
US10626146B2Apr 21, 2020
α4β7 thioether peptide dimer antagonists
PROTAGONIST THERAPEUTICS INC15 citations94
US10278957B2May 7, 2019
Opioid agonist peptides and uses thereof
PROTAGONIST THERAPEUTICS INC16 citations94
US10059744B2Aug 28, 2018
α4β7 thioether peptide dimer antagonists
PROTAGONIST THERAPEUTICS INC22 citations94
US9809623B2Nov 7, 2017
α4β7 peptide monomer and dimer antagonists
PROTAGONIST THERAPEUTICS INC26 citations94
US9714270B2Jul 25, 2017
a4B7 integrin thioether peptide antagonists
PROTAGONIST THERAPEUTICS INC27 citations94
US9273093B2Mar 1, 2016
α4β7 peptide dimer antagonists
PROTAGONIST THERAPEUTICS INC31 citations94
US10196424B2Feb 5, 2019
Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
PROTAGONIST THERAPEUTICS INC26 citations93
US10035824B2Jul 31, 2018
Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
PROTAGONIST THERAPEUTICS INC24 citations93
US10023614B2Jul 17, 2018
Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
PROTAGONIST THERAPEUTICS INC23 citations93
US11111272B2Sep 7, 2021
α4α7 peptide monomer and dimer antagonists
PROTAGONIST THERAPEUTICS INC10 citations86
US10787490B2Sep 29, 2020
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
PROTAGONIST THERAPEUTICS INC18 citations85
US10301371B2May 28, 2019
Cyclic monomer and dimer peptides having integrin antagonist activity
PROTAGONIST THERAPEUTICS INC19 citations85
US10729676B2Aug 4, 2020
Opioid agonist peptides and uses thereof
PROTAGONIST THERAPEUTICS INC10 citations83
US11041000B2Jun 22, 2021
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
PROTAGONIST THERAPEUTICS INC13 citations82
US10407468B2Sep 10, 2019
Methods for synthesizing α4β7 peptide antagonists
PROTAGONIST THERAPEUTICS INC13 citations82
US11840581B2Dec 12, 2023
α4β7 thioether peptide dimer antagonists
PROTAGONIST THERAPEUTICS INC1 citations73
US11472842B2Oct 18, 2022
Analogues of hepcidin mimetics with improved in vivo half lives
PROTAGONIST THERAPEUTICS INC5 citations72
US11753443B2Sep 12, 2023
Conjugated hepcidin mimetics
PROTAGONIST THERAPEUTICS INC3 citations70
US11884748B2Jan 30, 2024
Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
PROTAGONIST THERAPEUTICS INC0 citations62
US12552836B2Feb 17, 2026
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
PROTAGONIST THERAPEUTICS INC0 citations59
US12234300B2Feb 25, 2025
Conjugated hepcidin mimetics
PROTAGONIST THERAPEUTICS INC0 citations59
JANSSEN BIOTECH INC
3 patentsUS11845808B2Dec 19, 2023
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JANSSEN BIOTECH INC3 citations70
US12018057B2Jun 25, 2024
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JANSSEN BIOTECH INC1 citations57
US12478617B2Nov 25, 2025
Lipidated peptide inhibitors of interleukin-23 receptor
JANSSEN BIOTECH INC0 citations42